EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

Sources

Dose Diligence research deskSection 06 · Page 22 of 22Last updated 17 Nov 2026

Regulation, safety and state requirements

  1. FDA — GLP-1 compounding policy clarification: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. FDA — 503A essentially-copies guidance: https://www.fda.gov/media/98973/download
  4. FDA — September 18, 2026 Empower Pharmacy warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
  5. FDA — Bulk substances under section 503B: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  6. FDA — April 30, 2026 proposed GLP-1 bulks-list exclusions: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  7. FDA — Compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  8. California Board of Pharmacy — Sterile-compounding licences: https://www.pharmacy.ca.gov/applicants/sicp.shtml
  9. California Board of Pharmacy — Outsourcing-facility licences: https://www.pharmacy.ca.gov/applicants/outsrc.shtml
  10. FDA — Registered outsourcing facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  11. FDA — Form 483 questions and answers: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  12. FDA — Concerns about unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. FDA — Compounded injectable semaglutide dosing-error alert: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  14. FDA — DSCSA exemptions overview: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  15. FDA — August 6, 2026 small-dispenser exemption letter: https://www.fda.gov/media/194424/download
  16. HHS — Business-associate guidance and treatment-disclosure exceptions: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  17. HHS OIG — Telemedicine special fraud alert: https://oig.hhs.gov/documents/root/1045/sfa-telefraud.pdf

Published access terms and operational evidence

  1. LillyDirect — Patient FAQ: https://www.lilly.com/lillydirect/faq
  2. NovoCare — Healthcare-professional home-delivery page: https://www.novocare.com/hcp/delivery.html
  3. LillyDirect — Zepbound presentations, pricing and terms: https://www.lilly.com/lillydirect/zepbound
  4. LumiMeds — Pharmacy Partnerships Specialist job description: https://job-boards.greenhouse.io/lumimeds/jobs/4356730009

Expert-selection evidence

  1. Frier Levitt — Jesse C. Dresser profile: https://www.frierlevitt.com/attorney/jesse-c-dresser/
  2. Alliance for Pharmacy Compounding — Professional staff: https://a4pc.org/staff
  3. Northwestern — Robert F. Kushner profile: https://www.feinberg.northwestern.edu/sites/diabetes/members/profile.html?xid=11686
  4. ASHP — Michael Ganio’s January 2026 supply-chain testimony: https://news.ashp.org/News/ashp-news/2026/01/29/ashp-expert-on-drug-shortages-testifies-before-senate-committee
  5. ACHE 2026 Congress — Erin Fox speaker profile: https://ache2026.eventscribe.net/fsPopup.asp?PresenterID=2271052&efp=TFdYTktWT0cyNTg3OQ&mode=presenterinfo&rnd=0.3316944
  6. Drug Channels Institute — Adam Fein and leadership: https://drugchannelsinstitute.com/about/leadership/
  7. Informa Connect — Rae McMahan speaker profile: https://informaconnect.com/pbm-contracting/speakers/rae-mcmahan/

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. fda.gov · Source 3 ↗https://www.fda.gov/media/98973/download
  4. fda.gov · Source 4 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  6. fda.gov · Source 6 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  7. fda.gov · Source 7 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  8. pharmacy.ca.gov · Source 8 ↗https://www.pharmacy.ca.gov/applicants/sicp.shtml
  9. pharmacy.ca.gov · Source 9 ↗https://www.pharmacy.ca.gov/applicants/outsrc.shtml
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  11. fda.gov · Source 11 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  12. fda.gov · Source 12 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. fda.gov · Source 13 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  14. fda.gov · Source 14 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  15. fda.gov · Source 15 ↗https://www.fda.gov/media/194424/download
  16. hhs.gov · Source 16 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  17. oig.hhs.gov · Source 17 ↗https://oig.hhs.gov/documents/root/1045/sfa-telefraud.pdf
  18. lilly.com · Source 18 ↗https://www.lilly.com/lillydirect/faq
  19. novocare.com · Source 19 ↗https://www.novocare.com/hcp/delivery.html
  20. lilly.com · Source 20 ↗https://www.lilly.com/lillydirect/zepbound
  21. job-boards.greenhouse.io · Source 21 ↗https://job-boards.greenhouse.io/lumimeds/jobs/4356730009
  22. frierlevitt.com · Source 22 ↗https://www.frierlevitt.com/attorney/jesse-c-dresser/
  23. a4pc.org · Source 23 ↗https://a4pc.org/staff
  24. feinberg.northwestern.edu · Source 24 ↗https://www.feinberg.northwestern.edu/sites/diabetes/members/profile.html?xid=11686
  25. news.ashp.org · Source 25 ↗https://news.ashp.org/News/ashp-news/2026/01/29/ashp-expert-on-drug-shortages-testifies-before-senate-committee
  26. ache2026.eventscribe.net · Source 26 ↗https://ache2026.eventscribe.net/fsPopup.asp?PresenterID=2271052&efp=TFdYTktWT0cyNTg3OQ&mode=presenterinfo&rnd=0.3316944
  27. drugchannelsinstitute.com · Source 27 ↗https://drugchannelsinstitute.com/about/leadership/
  28. informaconnect.com · Source 28 ↗https://informaconnect.com/pbm-contracting/speakers/rae-mcmahan/
Section sources →